Blepharophimosis–Intellectual Disability Syndrome, Verloes Type

Blepharophimosis–intellectual disability syndrome, Verloes type is a very rare genetic syndrome. Children are born with narrow eye openings (blepharophimosis) and often droopy eyelids. They also have global developmental delay and intellectual disability. Many have small head size at birth (congenital microcephaly). Seizures can occur and may be severe, sometimes with a chaotic EEG pattern called hypsarrhythmia. Some babies are born with thumbs that bend inwards (adducted thumbs). Genital differences can be present. The thyroid is usually normal in this specific type. Because the condition is rare, doctors sometimes group it with related “blepharophimosis–intellectual disability syndromes,” but the Verloes type has its own pattern of features first described by Verloes and colleagues. Orpha.net+1

Blepharophimosis–intellectual disability syndrome, Verloes type is a very rare genetic condition. Children are born with blepharophimosis (narrow eye openings) and ptosis (droopy eyelids). They also have intellectual disability and developmental delay. Many children show microcephaly (a small head), low muscle tone, and later seizures. The seizures can be strong and early, and the EEG may show a pattern called hypsarrhythmia. Some children have adducted thumbs, genital differences, feeding problems, and a distinct facial appearance (for example, round face, large or bulbous nose, narrow mouth). Doctors group these signs together and give the diagnosis because this pattern is consistent in reported patients. The exact gene change for the Verloes type is not yet confirmed, but the overall syndrome belongs to a family of “blepharophimosis + intellectual disability” disorders. NCBI

Scientists think Verloes type sits in the wider family of blepharophimosis–intellectual disability conditions (BIDS). Some of those are caused by changes in a gene called KAT6B (these include Say–Barber–Biesecker–Young–Simpson syndrome and genitopatellar syndrome). But for Verloes type, the exact gene is not fully settled, and reports remain very limited. So, you may see overlap in clinical pictures but not always the same genetic answer. NCBI+2National Organization for Rare Disorders+2

Other names

Because the literature is small and older reports used different labels, you may encounter these names:

• Blepharophimosis with facial and genital anomalies and intellectual disability (a descriptive label for Verloes’ pattern). National Organization for Rare Disorders

• Blepharophimosis–intellectual disability syndrome (BIDS), Verloes type. Orpha.net

• Part of the blepharophimosis–intellectual disability syndromes group; sometimes discussed alongside Ohdo syndrome variants and KAT6B-related disorders in reviews. Orpha.net+1

Types

There is no universally accepted “Type 1 / Type 2” inside Verloes type itself. Clinicians usually sort patients by pattern and severity:

1. Classic Verloes pattern – blepharophimosis, significant developmental delay/intellectual disability, microcephaly, seizures (often severe), adducted thumbs, and genital differences. Orpha.net

2. Overlap presentations – children who share many Verloes features but also show findings seen in other BIDS conditions (for example, features reminiscent of KAT6B disorders), making classification difficult. NCBI+1

3. Severity bands – mild (few seizures, milder learning disability), moderate (persistent developmental disability, controlled seizures), and severe (hypsarrhythmia/infantile spasms, multiple congenital anomalies). This “severity” view is practical for care planning even if it is not a formal subtype. (Clinical practice inference based on reported spectra.) Orpha.net

---

Causes

Important context: For Verloes type specifically, the exact genetic cause is not fully established in the literature. The items below explain what is known or reasonably inferred from closely related BIDS conditions, especially those in the KAT6B spectrum. I note clearly where evidence comes from the broader BIDS/KAT6B group.

1. A rare, likely genetic condition – Verloes type is described as a genetic multiple congenital anomalies/dysmorphic syndrome. That means the cause is rooted in genes affecting early development. Orpha.net

2. De novo (new) variants – In related BIDS disorders (notably KAT6B-related), most changes arise de novo (new in the child, not inherited). This pattern may also explain many Verloes-type cases. NCBI+1

3. Developmental gene regulation defects – KAT6B and similar genes control histone acetylation, a process that turns other genes on or off during development. Disruption changes many organ programs at once. (From KAT6B biology.) MedlinePlus

4. Chromatin remodeling pathways – Wider chromatin regulators beyond KAT6B can, when altered, cause overlapping craniofacial, neurological, and skeletal findings. (Mechanism from KAT6B and chromatinopathies.) NCBI

5. Gene truncation or haploinsufficiency – In KAT6B disorders, truncating variants reduce functional protein (“haploinsufficiency”), driving a multisystem phenotype. Overlap cases near Verloes type may share this mechanism. Nature

6. Regulatory or deletion events – Deletions including or near key developmental genes can mimic single-gene variants and produce similar features. (Shown for KAT6B deletions.) Nature

7. Pathways for craniofacial patterning – Genes guiding eyelid and midface formation, when disrupted, lead to blepharophimosis and ptosis. (General pathogenesis from BIDS/Ohdo reviews.) ScienceDirect

8. Neurodevelopmental circuit formation defects – Abnormal early brain wiring can cause microcephaly, global delay, and seizures. (Consistent with Verloes descriptions of microcephaly and hypsarrhythmia.) Orpha.net

9. EEG network instability – Severe early epilepsies like hypsarrhythmia reflect diffuse cortical dysregulation rather than a single “spot” in the brain. (Mechanistic interpretation supported by Verloes reports.) Orpha.net

10. Limb patterning differences – Developmental gene changes can produce adducted thumbs and other hand/foot anomalies. Orpha.net

11. Endocrine development mostly spared – Unlike some BIDS/KAT6B types, congenital hypothyroidism is not typical in Verloes type, which often shows normal thyroid function. Orpha.net

12. Genital development differences – The same early signals that shape the face and brain also influence genital formation, explaining anomalies in some children. Orpha.net

13. Auditory/otoskeletal contributions – Middle/inner ear development can be variably affected, contributing to hearing problems noted across BIDS groups. (Group-level evidence.) Orpha.net

14. Cardiac patterning vulnerability – Congenital heart defects are well documented in related BIDS/KAT6B conditions; overlap is possible in Verloes-like cases. (Group-level evidence.) PMC

15. Dental/ectodermal development issues – Dental hypoplasia and enamel differences are common across the BIDS spectrum and may appear in overlaps. (Group-level evidence.) Orpha.net

16. Sporadic occurrence – Because cases are very rare, many families have only one affected child, supporting a sporadic, likely de novo origin. (Pattern across BIDS and Orphanet notes.) Orpha.net

17. Unknown/undiscovered genes – Some Verloes-type cases likely arise from genes not yet identified, which is common in ultra-rare syndromes. (Inference noted in Orphanet/MedGen scarcity.) Orpha.net+1

18. Variable expressivity – Even with the same pathway affected, the outward features can vary widely from child to child. (KAT6B disorder principle.) NCBI

19. Mosaicism (possible) – A parent could carry a variant in some body cells but not all (germline mosaicism). This explains very rare recurrences with negative parental tests in related disorders. (Genetic counseling principle from KAT6B disorders.) PubMed

20. Non-genetic causes are not the driver – Routine pregnancy or environmental factors do not explain the syndrome; the pattern points to underlying genetics. (By definition of a genetic multiple-anomalies syndrome.) Orpha.net

---

Symptoms and signs

1. Narrow eye openings (blepharophimosis) – Eyes look shorter horizontally; this can limit the field of vision and cause a characteristic facial appearance. Orpha.net

2. Droopy upper eyelids (ptosis) – Eyelids hang down and may cover the pupils, especially when tired; children may tilt the head back to see. Orpha.net

3. Global developmental delay – Delays in motor, language, and social milestones appear in infancy and early childhood. Orpha.net

4. Intellectual disability – Learning and problem-solving are affected to a variable degree; early therapy helps maximize skills. Orpha.net

5. Small head size (microcephaly) – The head measures below typical percentiles at birth; this often tracks with brain growth differences. Orpha.net

6. Seizures – Some infants develop seizures early; a few have hypsarrhythmia, a severe infantile EEG pattern that needs urgent treatment. Orpha.net

7. Adducted thumbs – Thumbs are drawn inwards; this can affect grasp and fine motor tasks. Orpha.net

8. Genital differences – Differences in genital development may be present and need individualized evaluation. Orpha.net

9. Characteristic facial features – The combination of eyelid shape, midface differences, and sometimes ear shape gives clinicians diagnostic clues. Orpha.net

10. Feeding difficulties in infancy – Poor suck or coordination can occur with global hypotonia and neurologic involvement (noted across the BIDS spectrum). Orpha.net

11. Hypotonia (low muscle tone) – Babies may feel “floppy.” This can delay rolling, sitting, and walking. (Common across related BIDS groups.) Genetic Rare Disease Center

12. Hearing problems – Some BIDS conditions include hearing impairment; careful screening is recommended in Verloes-like pictures. Orpha.net

13. Dental anomalies – Thin or underdeveloped teeth (dental hypoplasia) can occur in the larger BIDS group; dental care planning is useful. Orpha.net

14. Possible heart differences – Congenital heart defects are well recognized in related BIDS/KAT6B conditions; teams often screen for them when evaluating Verloes-type cases. PMC

15. Behavioral and learning challenges – Attention, communication, and adaptive skills often need ongoing supports through school years (general across intellectual disability syndromes).

Diagnostic tests

Goal: confirm the pattern, define needs, and search for an underlying genetic cause.

A) Physical examination

1. Detailed dysmorphology exam – A clinical geneticist looks closely at eyelids, face, ears, nose, mouth, palate, jaw, hands (thumb position), genitalia, and skin. This establishes the pattern for diagnosis. NCBI

2. Growth and head-circumference – Serial measures document microcephaly and growth trends; they also guide nutrition and seizure care. NCBI

3. Neurologic examination – Muscle tone, reflexes, posture, and coordination are checked to plan therapies and seizure care. NCBI

4. Ophthalmologic exam – An eye doctor evaluates lid function, corneal protection, tear film, and vision to decide on timing of ptosis/blepharophimosis surgery. NCBI

5. Orofacial exam – Palate integrity (cleft or high palate), jaw size, and feeding mechanics are assessed to support safe feeding and speech. NCBI

B) Manual/bedside tests

6. Eyelid measurements – Margin reflex distance, palpebral fissure length/height, and levator function are measured to document severity and plan surgery. (Standard oculoplastic assessment.)

7. Thumb function tests – Range of motion and grasp are checked; splinting or therapy is planned based on what the child can actively do.

8. Feeding/swallow screens – Bedside swallow checks identify choking risk; may prompt formal studies.

9. Developmental screening tools – Simple play-based tests (e.g., milestone checklists) chart delays and guide early-intervention referrals.

10. Hearing screens (OAE/AABR) – Quick screens in infants catch early hearing issues so that therapy can start promptly. (Hearing issues are documented in the BIDS family and checked in Verloes evaluations.) Orpha.net

C) Laboratory and pathological tests

11. Basic labs for nutrition – Iron studies, vitamin D, CMP, CBC help address anemia or malnutrition from feeding difficulties. (Supportive, not diagnostic.)

12. Metabolic screening (selective) – If seizures are severe or features are atypical, clinicians may check lactate, ammonia, acylcarnitine profile, or urine organic acids to rule out treatable metabolic causes. (General rare-disease practice.)

13. Endocrine tests when indicated – Thyroid function is usually normal in Verloes type (helpful clue), but testing confirms and rules out other causes of hypotonia or delay. NCBI

14. Genetic panels with RNA/functional follow-up (if a variant is found) – When sequencing finds a “variant of uncertain significance,” labs may propose RNA studies or family testing to clarify its effect. (Modern genetic workflow.)

D) Electrodiagnostic tests

15. EEG – Looks for seizure patterns. In infants, hypsarrhythmia supports a diagnosis of infantile spasms and requires urgent treatment. The EEG also tracks response to therapy. NCBI

16. Video-EEG monitoring – Links clinical events to EEG changes to choose the right seizure medicines.

17. Brainstem auditory evoked responses (BAER) – If behavioral hearing tests are hard, BAER objectively checks hearing pathways.

E) Imaging tests

18. Brain MRI – Reviews brain structure, myelination, and migration; can reveal corpus callosum differences or other anomalies sometimes seen across neurodevelopmental syndromes. (Imaging commonly reported in BIDS/related disorders.) PubMed

19. Craniofacial/airway imaging (as needed) – If cleft palate or airway issues are suspected, imaging helps surgical planning.

20. Ocular surface/tear-film imaging (clinic-based) – Slit-lamp biomicroscopy documents corneal exposure from ptosis or incomplete closure and guides lubrication or surgery.

Non-pharmacological treatments (therapies & other approaches)

1. Early developmental intervention (EI)
   Description. A structured, play-based program from infancy that blends speech-language, motor, cognitive, and social-emotional work. EI sessions coach parents to practice small skills many times a day (eye contact, reaching, babbling, turn-taking). Consistency and repetition build brain pathways in the first three years, when neuroplasticity is highest. Purpose. To boost learning, language, and daily-living skills despite global delay. Mechanism. Frequent, targeted practice strengthens synaptic connections in networks for attention, language, and movement; caregiver coaching generalizes gains into real life. Evidence link. Team-based management is standard for blepharophimosis disorders and rare neurodevelopmental syndromes. NCBI

2. Vision monitoring & amblyopia prevention
   Description. Regular pediatric ophthalmology visits check refraction, ocular alignment, and eyelid position; patching or glasses are used to prevent “lazy eye.” Purpose. Keep the better-seeing eye from suppressing the weaker eye so the brain wires normal binocular vision. Mechanism. Clear image delivery to the retina during the “critical period” drives normal cortical visual development; patching forces the weaker eye to work. Evidence link. Amblyopia risk is a central concern in blepharophimosis; coordinated ophthalmic care is recommended. NCBI

3. Speech-language therapy
   Description. Early, high-frequency sessions focus on pre-speech skills, receptive/expressive language, and safe feeding/swallow when needed. Purpose. Improve understanding, vocabulary, articulation, and social communication. Mechanism. Intensive, repetitive language input with multimodal cues builds phonologic and semantic networks and supports alternative communication when speech is limited. Evidence link. Multidisciplinary support is standard in BIDS/BPES care. NCBI

4. Occupational therapy (OT)
   Description. OT develops fine-motor control, hand use (important with adducted thumbs), sensory processing, and daily-living routines. Purpose. Independence in feeding, dressing, play, and school tasks. Mechanism. Task-specific, graded practice drives motor learning and adaptive behavior. Evidence link. Functional therapies are core in rare developmental syndromes. NCBI

5. Physical therapy (PT)
   Description. PT builds head control, sitting, standing, balance, and gait. Purpose. Maximize safe mobility and prevent contractures. Mechanism. Repetition and progressive challenge improve strength, posture, and neuro-motor coordination. Evidence link. Team-based care with PT is recommended for blepharophimosis syndromes. NCBI

6. Family genetic counseling
   Description. Counseling explains rarity, inheritance uncertainty (Verloes type often sporadic), and future pregnancy options. Purpose. Informed planning and reduced anxiety. Mechanism. Risk communication and coordination of testing/support services. Evidence link. Orphanet/GARD recommend genetic specialist involvement for BIDS subtypes. Orpha.net+1

7. Seizure-first-aid training for caregivers
   Description. Practical coaching on positioning, timing seizures, using rescue nasal benzodiazepines, and when to seek emergency help. Purpose. Reduce injury and status epilepticus risk. Mechanism. Rapid recognition and appropriate response shorten seizures and complications. Evidence link. FDA-labeled nasal midazolam/diazepam are standard for clusters; education is essential. FDA Access Data+1

8. Ketogenic or modified Atkins diet (specialist-supervised)
   Description. High-fat, very low-carb diets used for drug-resistant epilepsy; monitored by neurology/dietitians with labs and supplements. Purpose. Fewer seizures when medicines are insufficient. Mechanism. Ketosis alters brain energy use and neurotransmission (GABA/glutamate), stabilizing neuronal firing. Evidence link. Cochrane review supports benefit in refractory pediatric epilepsy. Cochrane Library+2Cochrane+2

9. Vagus nerve stimulation (VNS) evaluation for refractory seizures
   Description. Implantable device that intermittently stimulates the left vagus nerve; programmed by the epilepsy team. Purpose. Reduce seizure frequency/severity when medications fail. Mechanism. Neuromodulation of brain networks via vagal afferents lowers cortical excitability. Evidence link. FDA-approved for refractory partial-onset epilepsy in children and adults. FDA Access Data+1

10. Structured sleep hygiene
    Description. Fixed bedtime, low evening stimulation, consistent routines. Purpose. Better sleep lowers seizure threshold fluctuations and improves daytime behavior/learning. Mechanism. Stable circadian rhythm reduces cortical hyperexcitability. Evidence link. Standard supportive epilepsy care; integrated in multidisciplinary plans. NCBI

11. Behavioral therapy (ABA-informed strategies)
    Description. Positive behavior supports for irritability, self-injury, or attention issues common in neurodevelopmental disorders. Purpose. Safer behavior, more learning time. Mechanism. Reinforcement shaping reduces maladaptive cycles and teaches replacement skills. Evidence link. Multidisciplinary neurodevelopmental programs use behavioral therapy alongside meds when needed. NCBI

12. Nutritional support & safe feeding plans
    Description. Dietitian-guided calories, micronutrients, and texture safety; supplements as needed when growth lags. Purpose. Maintain growth and energy for therapy. Mechanism. Adequate nutrition supports neurodevelopment and immune function. Evidence link. Standard supportive care in rare pediatric epileptic encephalopathies. PMC

13. Educational accommodations (IEP/individualized plan)
    Description. School services for speech, OT/PT, visual supports, and testing accommodations. Purpose. Access learning with the right supports. Mechanism. Tailored goals and assistive tools improve participation and outcomes. Evidence link. Recommended for children with intellectual disability. Genetic Rare Disease Center

14. Safety proofing & fall prevention
    Description. Padded corners, supervision in water/heights, and seizure-aware environments. Purpose. Reduce injuries during seizures or motor delays. Mechanism. Environmental controls cut risk exposure. Evidence link. Standard epilepsy safety guidance. FDA Access Data

15. Regular hearing and dental evaluations
    Description. Screen for hearing loss and dental anomalies reported across BIDS spectrum. Purpose. Support speech/learning and oral health. Mechanism. Early detection enables timely aids and interventions. Evidence link. BIDS groups report related sensory and dental findings. Wikipedia

16. Endocrine/urologic assessment when genital anomalies present
    Description. Coordinate with pediatric specialists for undescended testes, ambiguous genitalia, or hormonal concerns. Purpose. Preserve fertility/hormonal health and prevent complications. Mechanism. Timely surgical/hormonal management when indicated. Evidence link. Genital anomalies reported in Verloes type. Orpha.net

17. Care navigation with rare-disease resources
    Description. Use GARD/Orphanet for specialist centers, trials, and family support. Purpose. Reduce isolation and speed problem-solving. Mechanism. Linking families to vetted resources improves adherence and outcomes. Evidence link. GARD offers individualized assistance for BIDS-Verloes. Genetic Rare Disease Center

18. Regular EEG/neurology follow-up
    Description. Track spasms, clusters, and background activity to adjust treatment. Purpose. Quicker control when patterns change. Mechanism. Data-driven therapy reduces cumulative seizure burden. Evidence link. Infantile spasms/hypsarrhythmia demand prompt, guideline-based management. PMC+1

19. Vision-focused surgical planning (staged approach)
    Description. Many children have staged eye surgeries—first epicanthus/telecanthus repair, then ptosis correction. Purpose. Open visual axis early and optimize symmetry and function. Mechanism. Structural correction reduces amblyopia risk and improves eyelid mechanics. Evidence link. Two-stage management is classic in blepharophimosis. Orpha.net

20. Parent peer-support & mental-health care
    Description. Counseling and peer groups reduce caregiver burnout and improve adherence to complex plans. Purpose. Sustain long-term caregiving capacity. Mechanism. Social support and coping skills buffer stress and improve child outcomes. Evidence link. Multidisciplinary models integrate family mental health. NCBI

---

Drug treatments

There is no drug approved specifically for “BIDS-Verloes.” Medications below are evidence-based for seizure types, irritability, spasticity, or rescue care that occur in this syndrome. Always prescribe via a pediatric neurologist; doses are individualized. FDA labeling citations are provided.

1. Levetiracetam (Keppra®)
   What & why (≈150 words). A broad-spectrum antiseizure drug used from childhood through adulthood as mono- or adjunct therapy for focal, generalized tonic-clonic, and myoclonic seizures. It has favorable kinetics, minimal interactions, IV/PO forms, and weight-based dosing, which helps in complex epilepsy syndromes. Behavioral side effects (irritability) can occur and should be monitored. Drug class. Antiseizure (SV2A modulator). Typical dosage/time. Pediatric dosing is weight-based in divided doses; titrate every 1–2 weeks per label. Purpose. Reduce seizure frequency and severity. Mechanism. Binds synaptic vesicle protein 2A, modulating neurotransmitter release and neuronal excitability. Key side effects. Somnolence, dizziness, mood/behavior changes. FDA label. FDA Access Data+2FDA Access Data+2

2. Topiramate (Topamax® / Trokendi XR®)
   What & why. Effective for focal and generalized seizures and Lennox-Gastaut syndrome; also has once-daily extended-release options. Class. Antiseizure (AMPA/kainate antagonism, GABA-A modulation, carbonic anhydrase inhibition). Dose/time. Start low, go slow; divided doses (Topamax) or once daily (XR). Purpose. Lower seizure burden. Mechanism. Multi-target dampening of excitatory transmission and enhancement of inhibition. Side effects. Cognitive slowing, weight loss, paresthesia, risk of metabolic acidosis/kidney stones; pregnancy cautions. FDA label. FDA Access Data+1

3. Lamotrigine (Lamictal®)
   What & why. Broad-spectrum adjunct or mono-therapy, useful in generalized epilepsy syndromes and drop attacks when carefully titrated. Class. Antiseizure (voltage-gated sodium channel blocker; glutamate release inhibitor). Dose/time. Slow upward titration to minimize rash risk. Purpose. Seizure reduction with a relatively clean cognitive profile. Mechanism. Stabilizes neuronal membranes by slowing repetitive firing. Side effects. Boxed warning for serious rash (SJS/TEN); dizziness; ataxia. FDA label. FDA Access Data+2FDA Access Data+2

4. Valproate / Divalproex (Depakote®, Depakene®, Depacon®)
   What & why. Broadly effective for generalized epilepsies and mixed seizure types; IV valproate is useful when oral dosing isn’t possible. Class. Antiseizure (GABAergic effects; sodium/calcium channel actions). Dose/time. Weight-based; titrate to clinical response and serum level. Purpose. Control difficult generalized patterns that may occur in syndromic epilepsy. Mechanism. Increases GABA, reduces high-frequency neuronal firing. Side effects. Teratogenicity with major neurodevelopmental risks; weight gain, tremor, thrombocytopenia, hepatotoxicity—use especially cautiously in females of child-bearing potential. FDA label. FDA Access Data+2FDA Access Data+2

5. Clobazam (Onfi® / Sympazan® oral film)
   What & why. Benzodiazepine approved for Lennox-Gastaut–associated seizures; often helpful as adjunct in generalized epilepsies. Class. Benzodiazepine (GABA-A positive allosteric modulator). Dose/time. Weight-based, typically twice daily; taper slowly to discontinue. Purpose. Add-on to reduce drop attacks and clusters. Mechanism. Enhances inhibitory GABA-A currents. Side effects. Sedation, tolerance, dependence risk, respiratory depression with opioids (boxed warnings). FDA label. FDA Access Data+3FDA Access Data+3FDA Access Data+3

6. Vigabatrin (Sabril®)
   What & why. First-line in infantile spasms due to TSC and used for refractory complex partial seizures; sometimes selected for hypsarrhythmia patterns. Class. Irreversible GABA transaminase inhibitor. Dose/time. Titrate to effect; REMS program due to vision toxicity. Purpose. Rapid suppression of spasms/hypsarrhythmia when appropriate. Mechanism. Increases brain GABA by blocking its breakdown. Side effects. Boxed warning for permanent visual field loss; sedation, weight gain. FDA label + guideline context. FDA Access Data+2FDA Access Data+2

7. Rescue: Midazolam nasal spray (Nayzilam®)
   What & why. Caregiver-administered rescue for seizure clusters in ≥12 years; easy to carry and use. Class. Benzodiazepine. Dose/time. Fixed nasal dose per label; may repeat once in a set interval. Purpose. Abort clusters and prevent ER visits/status. Mechanism. Rapid GABA-A potentiation. Side effects. Somnolence, respiratory depression (opioid interaction boxed warnings). FDA label. FDA Access Data+1

8. Rescue: Diazepam nasal spray (Valtoco®)
   What & why. Caregiver rescue for clusters in ≥6 years with weight-based dosing devices. Class. Benzodiazepine. Dose/time. 0.2–0.3 mg/kg per label; limits on frequency. Purpose. Home rescue to shorten clusters. Mechanism. GABA-A potentiation. Side effects. Sedation, respiratory depression; dependence potential. FDA label. FDA Access Data+1

9. Baclofen (oral granules; intrathecal for severe spasticity)
   What & why. For children with problematic spasticity that impedes care or therapy after brain injury/encephalopathy. Class. GABA-B receptor agonist (antispasticity). Dose/time. Oral divided dosing; intrathecal pumps reserved for refractory severe cases. Purpose. Reduce tone/pain, improve comfort and therapy participation. Mechanism. Inhibits spinal reflexes via GABA-B. Side effects. Sedation, hypotonia; intrathecal requires pump, screening dose, and close monitoring. FDA label. FDA Access Data+1

10. Risperidone (Risperdal®) for severe irritability associated with autism-spectrum features
    What & why. Some children with syndromic intellectual disability have severe irritability/self-injury; risperidone has pediatric FDA labeling for irritability in autism and may be considered by specialists. Class. Atypical antipsychotic (dopamine/serotonin antagonist). Dose/time. Weight-based, gradual titration. Purpose. Reduce aggression/self-injury that block learning and caregiving. Mechanism. Modulates dopaminergic/serotonergic circuits regulating behavior. Side effects. Weight gain, metabolic effects, EPS, sedation—monitor closely. FDA label. FDA Access Data+1

Clinical note: For infantile spasms/hypsarrhythmia, expert guidelines support ACTH or vigabatrin as effective short-term treatments; ACTH is often preferred outside TSC, but dosing is specialist-guided. (ACTH is not an FDA-labeled product page I can cite directly like the brands above, but the guideline evidence is strong.) PMC+2American Academy of Neurology+2

---

Dietary molecular supplements

Supplements do not replace antiseizure therapy. Evidence quality varies; use only with clinician oversight, especially with ketogenic or modified Atkins diets.

1. Medium-Chain Triglyceride (MCT) oil
   Description (≈150 words). MCT oil supplies ketogenic fats that more readily produce ketone bodies than long-chain fats. In supervised epilepsy diets, adding MCT can deepen or stabilize ketosis at lower total fat loads, making menus a bit more flexible and sometimes more tolerable. Dose. Titrated by dietitians (often teaspoons to tablespoons/day), balancing GI tolerance. Function. Support ketosis for seizure control. Mechanism. Rapid hepatic β-oxidation → ketone production → altered neuronal energetics and neurotransmission. Evidence. Ketogenic/MCT approaches reduce seizures in drug-resistant pediatric epilepsy. Cochrane Library+1

2. Vitamin D
   Description. Children on antiseizure drugs may have low vitamin D and bone risks. Supplementation corrects deficiency and supports bone health during limited outdoor activity or restricted diets. Dose. Lab-guided; commonly 400–1000 IU/day in children, adjusted to levels. Function/Mechanism. Restores calcium–bone metabolism; possible indirect anti-inflammatory effects. Evidence. Included in nutritional monitoring within ketogenic-diet programs. NCBI

3. Calcium
   Description. Paired with vitamin D to protect bone health when long-term ASMs or restrictive diets are used. Dose. Age-appropriate daily intake via food first; supplement only if intake is low. Function/Mechanism. Mineral for bone mineralization and neuromuscular function. Evidence. Standard micronutrient support in diet-based epilepsy therapy. NCBI

4. Selenium
   Description. Ketogenic diets may reduce selenium intake; deficiency can risk cardiomyopathy. Dose. Dietitian-guided (typically microgram doses meeting RDA). Function/Mechanism. Antioxidant enzyme (glutathione peroxidase) cofactor. Evidence. Part of monitored supplementation in keto programs. NCBI

5. Carnitine
   Description. Sometimes considered in children on valproate or strict keto with fatigue or hyperammonemia risk. Dose. Clinician-directed; only when deficiency/symptoms or ammonia issues arise. Function/Mechanism. Fatty-acid transport into mitochondria; may mitigate VPA-related hyperammonemia. Evidence. Utilized selectively in pediatric epilepsy nutrition protocols. NCBI

6. Magnesium
   Description. Corrects deficiency that can worsen neuromuscular irritability and sleep. Dose. Age-appropriate RDA; avoid excess due to diarrhea. Function/Mechanism. NMDA receptor modulation; neuromuscular stability. Evidence. Supportive micronutrient in restrictive diets. NCBI

7. Zinc
   Description. Ensures adequate growth and immune function on restrictive diets. Dose. RDA-based; food-first approach. Function/Mechanism. Cofactor in growth and immune enzymes. Evidence. Included in keto-diet supplementation checklists. NCBI

8. B-complex (especially B6 when appropriate)
   Description. General support for energy metabolism; note: high-dose pyridoxine is only for specific epilepsies (e.g., pyridoxine-dependent epilepsy)—not routine here. Dose. RDA-guided unless specialist indicates otherwise. Function/Mechanism. Coenzymes in neurotransmitter synthesis. Evidence. Nutrition programs individualize B vitamins; avoid megadoses without indication. NCBI

9. Folate
   Description. Supports growth and hematologic health; consider interactions with some ASMs. Dose. RDA-guided. Function/Mechanism. One-carbon metabolism for DNA synthesis. Evidence. Dietitian-guided supplementation in children on long-term ASMs. NCBI

10. Omega-3 fatty acids
    Description. May aid general brain and cardiovascular health; seizure benefit evidence is mixed and not a substitute for ASMs. Dose. Food-first (fish) or measured supplements. Function/Mechanism. Membrane fluidity and anti-inflammatory effects. Evidence. Considered adjunct in comprehensive nutrition—not a proven antiseizure monotherapy. NCBI

---

Immunity-booster / regenerative / stem-cell drugs

There are no FDA-approved “immune boosters,” regenerative drugs, or stem-cell medicines for BIDS-Verloes or for cognitive recovery in this condition. Using unregulated stem-cell products is risky and not recommended. The evidence-based path is seizure control, therapies, nutrition, sleep, and vision care; device options like VNS may help in refractory epilepsy. (See VNS FDA approvals.) FDA Access Data+1

If immune issues arise (e.g., from steroids used for infantile spasms), clinicians manage them with standard supportive care—not “immune boosters.”

---

Surgeries (procedures & why they’re done)

1. Medial canthoplasty (often with C-U or Y-V plasty; sometimes transnasal wiring)
   Why. Correct telecanthus and epicanthus inversus to align the inner eye corners and widen the palpebral fissure. What happens. Repositions the medial canthal tendon and re-drapes skin to reshape the inner eyelid folds. Often performed around ages 3–5, before or with later ptosis repair. Outcome. Improves symmetry and reduces amblyopia risk by opening the visual axis. aao.org+2PubMed+2

2. Ptosis repair (levator resection or frontalis suspension)
   Why. Lift droopy lids that block vision. What happens. If levator function is fair, the muscle is shortened; if poor, a frontalis sling connects eyelid to forehead muscle (using fascia lata or silicone). Outcome. Better eyelid elevation and field of view; staged after canthoplasty in classic plans. The Open Ophthalmology Journal+2JAMA Network+2

3. One-stage combined correction (selected centers/patients)
   Why. Some teams perform combined medial canthoplasty + lateral canthoplasty + ptosis correction in one session to reduce anesthesia episodes. Outcome. Good functional/cosmetic results in experienced hands; patient selection is key. Nature

4. Strabismus surgery (if ocular misalignment)
   Why. Straighten the eyes to promote binocular vision and reduce amblyopia risk. Outcome. Improves alignment and visual development when patching/glasses are insufficient. (Standard pediatric strabismus textbooks; often adjunct to eyelid surgeries.) NCBI

5. Urologic surgery (e.g., orchiopexy) when genital anomalies exist
   Why. Bring undescended testes into the scrotum to preserve fertility potential and reduce cancer risk; correct other anomalies as indicated. Outcome. Functional and long-term risk reduction. Orpha.net

---

Preventions (practical, family-friendly)

1. Prevent amblyopia: keep vision checks, glasses, and patching schedules. NCBI

2. Seizure triggers: regular sleep, avoid missed meds; manage fevers promptly. FDA Access Data

3. Infection vigilance on steroids (if used for spasms): sick-day plans. rch.org.au

4. Nutrition sufficiency: growth tracking and micronutrient checks on special diets. NCBI

5. Home safety for seizures: supervised bathing, padded edges, helmet if prescribed. FDA Access Data

6. Dental hygiene & hearing screens: protect speech and health. Wikipedia

7. Vaccinations per schedule: fewer preventable infections and fever-provoked seizures. (Standard pediatric practice.)

8. Sun & bone health: outdoor play + vitamin D/weight-bearing activity as allowed. NCBI

9. Emergency plan: rescue med on hand; caregivers trained. FDA Access Data+1

10. Regular neurology follow-up: adjust therapy early if seizures change. PMC

---

When to see a doctor (red flags)

• New or worsening seizures, clusters, or prolonged events (≥5 minutes). Use rescue medicine and seek urgent care. FDA Access Data

• Breathing problems, extreme sleepiness, or injury after a seizure. Emergency evaluation. FDA Access Data

• Vision blocking ptosis or concerns for amblyopia—earlier ophthalmology visit. NCBI

• Fevers or illness while on steroids/ACTH for spasms—call team immediately. rch.org.au

• Behavioral crisis (self-injury, aggression) or medication side effects (rash on lamotrigine; visual symptoms on vigabatrin; severe sedation on benzodiazepines). FDA Access Data+2FDA Access Data+2

---

What to eat” & “what to avoid

• Eat: whole foods, adequate protein, fruits/vegetables, and hydration to support therapy and growth; include dietitian-approved fats if on ketogenic/modified Atkins.

• Avoid: “cheating” on keto plans, as it breaks ketosis and can reduce seizure control. Limit: added sugar and ultra-processed snacks. Caffeine is not for children; avoid energy drinks. Alcohol is unsafe in kids/teens and can trigger seizures. Supplements only as the team advises (Vitamin D, calcium, selenium, etc., when indicated). Food triggers are uncommon, but note any consistent pattern and discuss with your clinician. (Diet details should be set by the neurology/dietitian team for each child.) Cochrane Library+1

FAQs

1. Is there a cure?
   Not yet. Care aims to maximize development and control seizures with therapies, nutrition, surgery for eyelids, and appropriate medicines/devices. Orpha.net

2. Will surgery fix vision?
   Surgery opens the eyelids and corrects inner corners to allow better visual development; it doesn’t fix the retina/brain. Early amblyopia care still matters. Orpha.net

3. Are seizures part of this syndrome?
   Many children with the Verloes type have early, severe epilepsy, sometimes with hypsarrhythmia. Prompt treatment improves outcomes. Orpha.net

4. What treats infantile spasms?
   Guidelines support ACTH or vigabatrin as first-line; choice depends on cause and child factors. PMC+1

5. Are rescue nasal sprays safe to keep at home?
   Yes, when prescribed and taught; midazolam and diazepam nasal sprays are FDA-labeled for seizure clusters with clear dosing limits. FDA Access Data+1

6. Can diet help?
   Ketogenic/modified Atkins diets can reduce seizures in drug-resistant epilepsy under expert supervision with labs and supplements. Cochrane Library

7. What about stem-cell therapy?
   No approved stem-cell or “regenerative” drug exists for BIDS-Verloes; avoid unregulated clinics. Consider evidence-based options like VNS if medication-resistant. FDA Access Data

8. Will my child walk and talk?
   Abilities vary. Early, intensive therapies and good seizure control improve the chances of reaching personal best function. NCBI

9. How often are eye checks needed?
   Frequently in early childhood (your ophthalmologist will set the schedule) to catch amblyopia and refractive errors. NCBI

10. What side effects should we watch for?

• Lamotrigine: any rash → urgent call.

• Vigabatrin: visual field changes → mandatory eye program.

• Benzodiazepines: sedation/respiratory depression, especially with opioids. FDA Access Data+2FDA Access Data+2

11. When is surgery done?
    Often staged: canthoplasty in early childhood, followed by ptosis repair months later; timing is individualized. Orpha.net

12. Is VNS a big operation?
    It’s an implant under the skin with a lead to the vagus nerve; most children go home quickly and settings are adjusted in clinic. Used only for refractory cases. FDA Access Data

13. Can we prevent seizures completely?
    Many improve a lot; some remain refractory. Combining medicines, diets, rescue plans, and, if needed, devices gives the best chance. Cochrane Library

14. Will my next baby have this?
    Inheritance is not well-defined in Verloes type; a genetic counselor can discuss testing options and risks. Orpha.net

15. Where can we find experts and support?
    GARD and Orphanet list clinics, information, and community resources for rare diseases. Genetic Rare Disease Center

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 28, 2025.